聚乙二醇非格司亭
医学
多西紫杉醇
发热性中性粒细胞减少症
菲格拉斯汀
乳腺癌
环磷酰胺
内科学
安慰剂
中性粒细胞减少症
化疗
肿瘤科
不利影响
外科
癌症
病理
替代医学
作者
Yoshimasa Kosaka,Yoshiaki Rai,Norikazu Masuda,Toshimi Takano,Toshiaki Saeki,Seigo Nakamura,Ryutaro Shimazaki,Yoshinori Ito,Yutaka Tokuda,Kazuo Tamura
标识
DOI:10.1007/s00520-014-2597-1
摘要
PURPOSE: Pegfilgrastim is a pegylated form of filgrastim, a recombinant protein of granulocyte colony-stimulating factor, that is used to reduce the risk of febrile neutropenia (FN). Here, we report the results of a phase III trial of pegfilgrastim in breast cancer patients receiving docetaxel and cyclophosphamide (TC) chemotherapy. METHODS: We conducted a double-blind, placebo-controlled, randomized trial to determine the efficacy of pegfilgrastim in reducing the risk of FN in early-stage breast cancer patients. A total of 351 women (177 in the pegfilgrastim group and 174 in the placebo group) between 20 and 69 years of age with stage I-III invasive breast carcinoma who were to receive TC chemotherapy (docetaxel 75 mg/m(2) and cyclophosphamide 600 mg/m(2) every 3 weeks) as either neoadjuvant or adjuvant therapy were enrolled; 346 of these patients were treated with either pegfilgrastim (n = 173) or placebo (n = 173). RESULTS: The incidence of FN was significantly lower in the pegfilgrastim group than in the placebo group (1.2 vs. 68.8 %, respectively; P < 0.001). In addition, patients in the pegfilgrastim group required less hospitalization and antibiotics for FN. Most adverse events were consistent with those expected for breast cancer subjects receiving TC chemotherapy. CONCLUSIONS: Pegfilgrastim is safe and significantly reduces the incidence of FN in breast cancer patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI